ATAI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ATAI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.
As of today, ATAI Life Sciences NV's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.
For the Biotechnology subindustry, ATAI Life Sciences NV's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, ATAI Life Sciences NV's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:
* The bar in red indicates where ATAI Life Sciences NV's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.
ATAI Life Sciences NV (NAS:ATAI) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation
Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.
In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.
Thank you for viewing the detailed overview of ATAI Life Sciences NV's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.
Florian Brand | officer: See Remarks | C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014 |
Anne Nagengast Johnson | officer: Chief Accounting Officer | C/O ATAI LIFE SCIENCES N.V., WALLSTRASSE 16, BERLIN 2M 10179 |
Apeiron Investment Group Ltd. | 10 percent owner | BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605 |
Sahil Kirpekar | officer: Chief Business Officer | C/O ATAI LIFE SCIENCES N.V., WALLSTRASSE 16, BERLIN 2M 10179 |
Stephen Bardin | officer: Chief Financial Officer | C/O ATAI LIFE SCIENCES N.V., KRAUSENSTRASSE 9-10, BERLIN 2M 10117 |
Gregory L Weaver | officer: Chief Financial Officer | 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107 |
Andrea Heslin Smiley | director | 600 LEE ROAD, SUITE 100, WAYNE PA 19087 |
Michael Auerbach | director | 158 HESTER STREET, APT 7F, NEW YORK NY 10013 |
Amir H Kalali | director | 4350 EXECUTIVE DRIVE SUITE 325, SAN DIEGO CA 92121 |
Christian Angermayer | director, 10 percent owner | BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605 |
Rosnay Alexis De | director | C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014 |
Srinivas Rao | officer: See Remarks | C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014 |
Sabrina Martucci Johnson | director | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Jason Camm | director | C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014 |
Presight Ii, Lp | 10 percent owner | C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014 |
From GuruFocus
By Business Wire Business Wire • 11-04-2022
By Value_Insider Value_Insider • 12-16-2022
By Value_Insider Value_Insider • 11-29-2022
By Marketwired • 08-08-2023
By sperokesalga sperokesalga • 05-11-2023
By Marketwired • 09-14-2023
By Tiesvg Tiesvg • 12-23-2022
By Marketwired • 08-10-2023
By sperokesalga sperokesalga • 06-01-2023
By GuruFocus Research • 09-15-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.